The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

Eli Lilly and Company (NYSE:LLY) ranks as the 10th safest stock to invest in now. Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company that sells products to 125 countries and has offices ...

On Friday, TD Cowen reaffirmed its positive stance on shares of Eli Lilly (NYSE:LLY), maintaining a Buy rating and a price target of $1,050.00 for the pharmaceutical company's shares. The ...